Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 3/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.81 |
| ▸ | POLB | P06746 | 1/20 | 0.81 |
| ▸ | GAA | P10253 | 1/20 | 0.81 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.81 |
| ▸ | HPGD | P15428 | 1/20 | 0.81 |
| ▸ | TSHR | P16473 | 1/20 | 0.81 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | DHFR | P00374 | 6/20 | 0.55 |
| ▸ | GART | P22102 | 2/20 | 0.55 |
| ▸ | ATIC | P31939 | 1/20 | 0.55 |
| ▸ | FPGS | Q05932 | 5/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15853537 | 1.00 | TYMS (0.81) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL16731734 | 0.95 | TYMS (0.80) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL17084046 | 0.95 | TYMS (0.80) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL21664561 | 0.94 | TYMS (0.85) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL28859397 | 0.93 | TYMS (0.83) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL22803356 | 0.92 | AKR1B1 (0.83) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL6129887 | 0.92 | TYMS (0.72) | TYMSKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL18897639 | 0.92 | TYMS (0.74) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL2322432 | 0.92 | TYMS (0.84) | TYMSKDM4EMEN1ALDH1A1POLB | |
| Folic Acid SCHEMBL28158543 | 0.92 | TYMS (0.84) | TYMSKDM4EMEN1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240285776-A1 | SMALL MOLECULE-BASED BI-SPECIFIC IMMUNE CELL TETHERS AND THEIR USE IN THE TREATMENT OF ENVELOPED VIRUS INFECTION | PURDUE RESEARCH FOUNDATION | 2024-08-29 | — | — | US | claimed |
| EP-4337663-A2 | SMALL MOLECULE-BASED BI-SPECIFIC IMMUNE CELL TETHERS AND THEIR USE IN THE TREATMENT OF ENVELOPED VIRUS INFECTION | Purdue Research Foundation (US) | 2024-03-20 | — | — | EP | claimed |
| WO-2022241262-A2 | SMALL MOLECULE-BASED BI-SPECIFIC IMMUNE CELL TETHERS AND THEIR USE IN THE TREATMENT OF ENVELOPED VIRUS INFECTION | PURDUE RESEARCH FOUNDATION (US) | 2022-11-17 | — | — | WO | claimed |
| US-20240285776-A1 | SMALL MOLECULE-BASED BI-SPECIFIC IMMUNE CELL TETHERS AND THEIR USE IN THE TREATMENT OF ENVELOPED VIRUS INFECTION | PURDUE RESEARCH FOUNDATION | 2024-08-29 | — | — | US | disclosed |
| EP-4337663-A2 | SMALL MOLECULE-BASED BI-SPECIFIC IMMUNE CELL TETHERS AND THEIR USE IN THE TREATMENT OF ENVELOPED VIRUS INFECTION | Purdue Research Foundation (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20230331767-A1 | TARGETED STEROID COMPOUNDS | PURDUE RESEARCH FOUNDATION | 2023-10-19 | — | — | US | disclosed |
| WO-2022241262-A2 | SMALL MOLECULE-BASED BI-SPECIFIC IMMUNE CELL TETHERS AND THEIR USE IN THE TREATMENT OF ENVELOPED VIRUS INFECTION | PURDUE RESEARCH FOUNDATION (US) | 2022-11-17 | — | — | WO | disclosed |
| EP-4087580-A1 | TARGETED STEROID COMPOUNDS | Purdue Research Foundation (US) | 2022-11-16 | — | — | EP | disclosed |
| CN-115003308-A | Targeted steroid compounds | 普渡研究基金会 | 2022-09-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331767-A1 | TARGETED STEROID COMPOUNDS | CYP11B2, FOLR2, CYP11B1 | TYMS 307/4885KDM4E 4622/4885MEN1 1175/4885 |
| US-20240285776-A1 | SMALL MOLECULE-BASED BI-SPECIFIC IMMUNE CELL TETHERS AND THEIR USE IN THE TREATMENT OF ENVELOPED VIRUS INFECTION | CD4, HAVCR2, EPCAM | TYMS 2945/4885KDM4E 2396/4885MEN1 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.